SCHEMBL5201362

SCHEMBL5201362

NCCCC#CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6014383 0.93 NFKB1 (0.42)
SCHEMBL19547960 0.84 TBXAS1 (0.48)
SCHEMBL4972648 0.84 TBXAS1 (0.44)
SCHEMBL7206466 0.80
SCHEMBL4972765 0.78 TBXAS1 (0.38)
SCHEMBL15141520 0.75
SCHEMBL4970367 0.75 PTPN7 (0.50)
SCHEMBL1088162 0.75
SCHEMBL9746630 0.75
SCHEMBL15548365 0.75 TBXAS1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10471057-B2 Toxic RNA inhibitors self-assembled in situ THE SCRIPPS RESEARCH INSTITUTE (US) 2019-11-12 US disclosed
US-20190151310-A1 TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU THE SCRIPPS RESEARCH INSTITUTE 2019-05-23 US disclosed
US-10220031-B2 Toxic RNA inhibitors self-assembled in situ THE SCRIPPS RESEARCH INSTITUTE (US) 2019-03-05 US disclosed
US-20170143703-A1 TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU THE SCRIPPS RESEARCH INSTITUTE 2017-05-25 US disclosed
EP-3169404-A1 TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU The Scripps Research Institute (US) 2017-05-24 EP disclosed
CN-106714908-A In situ self-assembled toxic RNA inhibitors 斯克利普斯研究院 2017-05-24 CN disclosed
WO-2016011348-A1 TOXIC RNA INHIBITORS SELF-ASSEMBLED IN SITU THE SCRIPPS RESEARCH INSTITUTE (US) 2016-01-21 WO disclosed
EP-0773950-B1 LINKED PEPTIDE NUCLEIC ACIDS ISIS PHARMACEUTICALS INC (US) 2007-08-22 EP disclosed
US-7078406-B2 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) 2006-07-18 US disclosed
US-7071195-B2 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2006-07-04 US disclosed
WO-2003031419-A1 SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-04-17 WO disclosed
US-6451968-B1 HOOGSTEEN TYPE BASE PAIRING IN TRIPLEX MOTIF; DIAGNOSIS; HEAT RESISTANCE; DETECTION OF POINT MUTATIONS, RESTRICTION ENZYME SITES, AND TRANSCRIPTION INHIBITION ISIS PHARMACEUTICALS, INC. 2002-09-17 US disclosed
US-6441130-B1 FORM TRIPLE STRANDED STRUCTURES WITH NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. 2002-08-27 US disclosed
US-20020115715-A1 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders DAX SCOTT L (US) 2002-08-22 US disclosed
EP-1202986-A1 AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS Ortho-McNeil Pharmaceutical, Inc. (US) 2002-05-08 EP disclosed
US-6380224-B1 FOR THERAPY OF EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION AND ANXIETY ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-04-30 US disclosed
WO-2001009120-A1 AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-02-08 WO disclosed
EP-0773950-A4 LINKED PEPTIDE NUCLEIC ACIDS ISIS PHARMACEUTICALS INC (US) 2000-05-17 EP disclosed
EP-0773950-A1 LINKED PEPTIDE NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 1997-05-21 EP disclosed
WO-1996002558-A1 LINKED PEPTIDE NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 1996-02-01 WO disclosed